On August 21, AKESO fell 3.41% in regular trading to HK$90.7, with turnover of HK$453 million. The decline follows a sharp 9.63% surge in the previous session when innovative drug stocks rallied broadly.

On the news front, the stock continues to exhibit heightened volatility following the August 12 approval of ivonescimab's third indication for first-line treatment of squamous non-small cell lung cancer. That milestone had previously driven an eight-day rally, after which profit-taking pressure persisted for multiple sessions, pulling the stock down over 10% from its highs. Yesterday's sector-wide surge — which saw peers such as Sino Biopharmaceutical gain over 20% and CSPC Pharmaceutical rise over 16% — triggered a technical rebound, but selling pressure has returned today. The broader biotech sector is mixed, with CanSino Biologics down 11.79% and Everest Medicines down 10.16%, reflecting continued risk-off sentiment. Institutionally, analysts maintain buy ratings with an average target price of HK$170.79, implying significant upside from current levels ahead of the company's interim results release on August 27.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)